CYP7A1
CYP7A1 (Cytochrome P450 7A1), also known as cholesterol 7 alpha-hydroxylase, is an enzyme that in humans is encoded by the CYP7A1 gene. This enzyme plays a crucial role in the cholesterol metabolism pathway, specifically in the biosynthesis of bile acids from cholesterol. The activity of CYP7A1 is the rate-limiting step in this process, making it a key enzyme in maintaining cholesterol homeostasis and lipid digestion.
Function[edit | edit source]
CYP7A1 catalyzes the first and rate-limiting step in the classical pathway of bile acid synthesis. It converts cholesterol into 7-alpha-hydroxycholesterol, which is then further processed into bile acids. These bile acids are essential for the emulsification and absorption of dietary fats in the intestine. Through its action, CYP7A1 not only facilitates lipid digestion but also plays a pivotal role in reducing the cholesterol levels in the body.
Gene[edit | edit source]
The CYP7A1 gene is located on chromosome 8q11-q12 and consists of 6 exons. The regulation of this gene is complex and is influenced by various hormonal and dietary factors. Notably, bile acids themselves negatively regulate the expression of CYP7A1 through a feedback inhibition mechanism to prevent excessive bile acid production.
Clinical Significance[edit | edit source]
Alterations in the activity or expression of CYP7A1 can have significant clinical implications. Increased activity of CYP7A1 can lead to an enhanced conversion of cholesterol into bile acids, potentially lowering blood cholesterol levels. Conversely, reduced CYP7A1 activity can contribute to hypercholesterolemia and gallstone formation due to the accumulation of cholesterol and decreased bile acid synthesis.
Furthermore, genetic variations in the CYP7A1 gene have been associated with susceptibility to various metabolic disorders, including hypercholesterolemia, gallstones, and non-alcoholic fatty liver disease (NAFLD). Understanding the regulation and function of CYP7A1 is therefore critical for developing therapeutic strategies for these conditions.
Pharmacology[edit | edit source]
Given its central role in cholesterol and bile acid metabolism, CYP7A1 is a target for pharmacological intervention in the treatment of hypercholesterolemia and related metabolic disorders. Drugs that inhibit CYP7A1 activity can potentially increase cholesterol levels, whereas agents that upregulate CYP7A1 expression or activity may have therapeutic benefits in lowering plasma cholesterol levels.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD